Asm-024 cation

DB19385InvestigationalSmall molecule

Asm-024 cation is under investigation in clinical trial NCT01855230 (Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)).

Mechanism: Pharmacologically active on Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M1, and Muscarinic acetylcholine receptor M2
Curator reviewed
Formula / weight: C₁₅H₂₅N₂ · 233.378 g/mol (avg)
Also known as: 1,1-diethyl-4-phenylhomopiperazinium · 1h-1,4-diazepinium, 1,1-diethylhexahydro-4-phenyl-
Code names: ASM-024

Resolves to

Compound

UNII7N7MB1SWWJCAS1609534-88-4

Structure

InChIKeyDAPFMGRCDFSUSN-UHFFFAOYSA-NSMILESCC[N+]1(CC)CCCN(CC1)C1=CC=CC=C1

Targets

P20309CHRM3P11229CHRM1P08172CHRM2P36544CHRNA7

What you can answer from here — as of August 31, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Asm-024 cation, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account